Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

Aug. 26 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-30	CN¥45.01	-7.25%	1,654,701
26-07-29	CN¥48.53	+0.52%	1,203,800
26-07-28	CN¥48.28	-4.15%	835,899
26-07-27	CN¥50.37	+0.30%	990,400
26-07-24	CN¥50.22	-4.94%	991,399

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-30			5-day change	1st Jan Change
45.01 ^CNY	-7.25%		-14.80%	-24.57%

Apr. 28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	3.55B 525M 456M 424M 391M 736M 50.17B 750M 5.02B 1.96B 24.92B 1.97B 1.93B 83.79B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	3.88B 574M 498M 463M 427M 804M 54.78B 819M 5.48B 2.15B 27.21B 2.15B 2.11B 91.49B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	30.57%	Yield 2024 *	-	Yield 2025	-

Apr. 28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
Feb. 26	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
Feb. 24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
Jan. 20	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
Dec. 04	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
25-10-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-12	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
25-09-29	Duorui Pharma Expects Control Change Amid Parents' Plan	MT
25-09-28	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.	CI

1 day	-7.25%
1 week	-14.80%
Current month	-21.05%
1 month	-21.05%
3 months	-46.06%
6 months	-27.58%
Current year	-24.57%

Tibet Duo Rui Pharmaceutical Co., Ltd. Stock

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news : Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	44.55	50.9
1 month	44.55	66.68
Current year	44.55	98.29
1 year	34.2	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	2018-11-30
Chao Li DFI	Director of Finance/CFO	47	2017-04-30
Fen Jin DFI	Director of Finance/CFO	46	2017-11-30

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	2017-11-30
Shao Zhong Zhang BRD	Director/Board Member	70	2020-02-20
Qin Deng BRD	Director/Board Member	58	2020-02-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-7.25%	-14.80%	+16.61%	+80.33%	525M
ELI LILLY AND COMPANY	-4.55%	-2.61%	+51.95%	+151.91%	1,030B
JOHNSON & JOHNSON	-3.66%	-1.33%	+52.95%	+46.62%	617B
ABBVIE INC.	-2.24%	+0.19%	+35.97%	+70.64%	455B
ROCHE HOLDING AG	+0.57%	+0.25%	+38.47%	+31.56%	350B
NOVARTIS AG	+0.62%	+0.61%	+35.56%	+40.20%	299B
ASTRAZENECA PLC	+0.14%	+0.73%	+12.70%	+14.09%	265B
NOVO NORDISK A/S	-6.37%	-4.20%	-2.34%	-43.76%	225B
AMGEN INC.	0.00%	+4.34%	+28.63%	+64.00%	209B
GILEAD SCIENCES, INC.	-1.09%	+0.32%	+14.40%	+70.80%	163B
Average	-1.48%	+3.31%	+28.49%	+52.64%	361.32B
Weighted average by Cap.	-0.69%	+4.87%	+38.13%	+71.74%

	2024	2025
Net sales	241M 35.58M 30.91M 28.7M 26.47M 49.86M 3.4B 50.76M 340M 133M 1.69B 134M 131M 5.67B	154M 22.8M 19.8M 18.39M 16.96M 31.94M 2.18B 32.52M 218M 85.24M 1.08B 85.61M 83.74M 3.64B
Net income	-62.67M -9.27M -8.05M -7.47M -6.89M -12.98M -885M -13.22M -88.49M -34.65M -439M -34.8M -34.04M -1.48B	-102M -15.11M -13.12M -12.19M -11.24M -21.17M -1.44B -21.55M -144M -56.49M -716M -56.73M -55.49M -2.41B
Net Debt	135M 19.92M 17.3M 16.06M 14.81M 27.91M 1.9B 28.41M 190M 74.46M 944M 74.79M 73.15M 3.18B	327M 48.31M 41.97M 38.97M 35.94M 67.7M 4.61B 68.92M 461M 181M 2.29B 181M 177M 7.7B